None
Quote | Sanofi Contingent Value Right (Expiring 12/31/2020) (NASDAQ:GCVRZ)
Last: | $ |
---|---|
Change Percent: | -0.48% |
Open: | $0.8692 |
Close: | $0.8702 |
High: | $0.8744 |
Low: | $0.8692 |
Volume: | 7,273 |
Last Trade Date Time: | 02/12/2020 04:52:07 pm |
News | Sanofi Contingent Value Right (Expiring 12/31/2020) (NASDAQ:GCVRZ)
2024-04-25 01:38:35 ET More on Sanofi: Sanofi: My Top Pick In Big Pharma Sanofi reportedly lining up banks for consumer products spinoff Sanofi succeeds in late-stage trial for blood disorder candidate Read the full article on Seeking Alpha For furthe...
2024-04-23 09:44:51 ET More on Sanofi Sanofi: My Top Pick In Big Pharma Sanofi (SNY) Barclays 26th Annual Global Healthcare Conference (Transcript) Sanofi (SNY) Leerink Partners Global Biopharma Conference (Transcript) Sanofi reportedly settles 4K Zantac case...
Message Board Posts | Sanofi Contingent Value Right (Expiring 12/31/2020) (NASDAQ:GCVRZ)
Subject | By | Source | When |
---|---|---|---|
Sanofi announces settlement agreement related to Contingent Value | Enterprising Investor | investorshub | 12/24/2019 8:09:00 PM |
It's been a long time since anyone has | greendragon- | investorshub | 10/25/2019 11:07:24 PM |
New Findings In The $GCVRZ Lawsuit (10/02/18) | Enterprising Investor | investorshub | 11/24/2018 5:55:48 AM |
U.S. District Court | Enterprising Investor | investorshub | 11/24/2018 5:50:03 AM |
Why the volume? What the $ run | JHOGG | investorshub | 01/18/2017 4:38:16 PM |
News, Short Squeeze, Breakout and More Instantly...
Sanofi Contingent Value Right (Expiring 12/31/2020) Company Name:
GCVRZ Stock Symbol:
NASDAQ Market:
* The British Pharmacological Society awards Cablivi® (caplacizumab), the first new treatment in 30 years for acquired Thrombotic Thrombocytopenic Purpura (aTTP), Drug Discovery of the Year 2020 * TTP is a rare blood clotting disorder with 330 people known to be affected i...